Daniel E. Geffken - Net Worth and Insider Trading
Daniel E. Geffken Net Worth
The estimated net worth of Daniel E. Geffken is at least $1 dollars as of 2024-11-29. Daniel E. Geffken is the Director of Windtree Therapeutics Inc and owns about 2 shares of Windtree Therapeutics Inc (WINT) stock worth over $1. Daniel E. Geffken is also the INTERIM CFO of Eloxx Pharmaceuticals Inc and owns about 1,250 shares of Eloxx Pharmaceuticals Inc (ELOX) stock worth over $0. Details can be seen in Daniel E. Geffken's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Daniel E. Geffken has not made any transactions after 2021-11-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Daniel E. Geffken
Daniel E. Geffken Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Daniel E. Geffken owns 7 companies in total, including Windtree Therapeutics Inc (WINT) , Adhera Therapeutics Inc (ATRX) , and Eloxx Pharmaceuticals Inc (ELOX) among others .
Click here to see the complete history of Daniel E. Geffken’s form 4 insider trades.
Insider Ownership Summary of Daniel E. Geffken
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| WINT | Windtree Therapeutics Inc | 2020-05-22 | director |
| ATRX | Adhera Therapeutics Inc | 2014-05-13 | Interim CFO |
| ELOX | Eloxx Pharmaceuticals Inc | 2021-11-29 | Chief Financial Officer |
 | | 2021-01-07 | Chief Financial Officer |
| | 2021-10-05 | Chief Financial Officer |
| | 2023-10-26 | Chief Financial Officer |
| | 2023-03-20 | Interim CFO |
Daniel E. Geffken Latest Holdings Summary
Daniel E. Geffken currently owns a total of 2 stocks. Among these stocks, Daniel E. Geffken owns 2 shares of Windtree Therapeutics Inc (WINT) as of May 22, 2020, with a value of $1 and a weighting of 90.7%. Daniel E. Geffken also owns 1,250 shares of Eloxx Pharmaceuticals Inc (ELOX) as of November 29, 2021, with a value of $0 and a weighting of 9.3%.
Latest Holdings of Daniel E. Geffken
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| WINT | Windtree Therapeutics Inc | 2020-05-22 | 2 | 0.61 | 1 |
| ELOX | Eloxx Pharmaceuticals Inc | 2021-11-29 | 1,250 | 0.00 | 0 |
Holding Weightings of Daniel E. Geffken
Daniel E. Geffken Form 4 Trading Tracker
According to the SEC Form 4 filings, Daniel E. Geffken has made a total of 1 transactions in Windtree Therapeutics Inc (WINT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Windtree Therapeutics Inc is the acquisition of 2 shares on May 22, 2020, which cost Daniel E. Geffken around $15,000.
According to the SEC Form 4 filings, Daniel E. Geffken has made a total of 1 transactions in Eloxx Pharmaceuticals Inc (ELOX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Eloxx Pharmaceuticals Inc is the acquisition of 1,250 shares on November 29, 2021, which cost Daniel E. Geffken around $36,000.
Insider Trading History of Daniel E. Geffken
- 1
Daniel E. Geffken Trading Performance
GuruFocus tracks the stock performance after each of Daniel E. Geffken's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Daniel E. Geffken is -17.5%. GuruFocus also compares Daniel E. Geffken's trading performance to market benchmark return within the same time period. The performance of stocks bought by Daniel E. Geffken within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Daniel E. Geffken's insider trading performs compared to the benchmark.
Performance of Daniel E. Geffken
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -7.47 | | | | | |
| Relative Return to S&P 500(%) | -11.7 | | | | | |
Daniel E. Geffken Ownership Network
Daniel E. Geffken Owned Company Details
What does Windtree Therapeutics Inc do?
Who are the key executives at Windtree Therapeutics Inc?
Daniel E. Geffken is the director of Windtree Therapeutics Inc. Other key executives at Windtree Therapeutics Inc include director & Chief Executive Officer Craig Fraser , VP & Controller & & CAO Jamie Mcandrew , and SVP & CFO John P. Hamill .
Windtree Therapeutics Inc (WINT) Insider Trades Summary
Over the past 18 months, Daniel E. Geffken made no insider transaction in Windtree Therapeutics Inc (WINT). Other recent insider transactions involving Windtree Therapeutics Inc (WINT) include a net purchase of 10,431 shares made by Craig Fraser ,
In summary, during the past 3 months, insiders sold 0 shares of Windtree Therapeutics Inc (WINT) in total and bought 5,431 shares, with a net purchase of 5,431 shares. During the past 18 months, 0 shares of Windtree Therapeutics Inc (WINT) were sold and 5,709 shares were bought by its insiders, resulting in a net purchase of 5,709 shares.
Windtree Therapeutics Inc (WINT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Windtree Therapeutics Inc Insider Transactions
Daniel E. Geffken Mailing Address
Above is the net worth, insider trading, and ownership report for Daniel E. Geffken. You might contact Daniel E. Geffken via mailing address: Damonmill Square, Suite 6a, Concord Ma 01742.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
